A drugmaker with one of the world's top-selling drugs Regeneron (NASDAQ: REGN) is a well-established biotech company that generates consistent revenue and profits. However, the drugmaker ...

Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options begin trading today, for the May 23rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options begin trading this week, for the November 21st expiration. One of the key inputs that goes into the price an option ...

Regeneron has more growth opportunities ahead ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in 1993 in Alexandria, VA., by brothers David and Tom ...

Below is Validea's guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow, REGN rates highest using our Value Investor model based on the published ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Regeneron’s debt is the second lowest among ... The next closest company, Vertex Pharmaceuticals (NASDAQ: VRTX), has a current ratio of 2.7x. This shows the firm’s strong liquidity position ...

Intellia has collaborated with Regeneron Pharmaceuticals REGN for the development of nex-z. Nex-z is part of the company’s co-development and co-promotion agreement with Regeneron. While NTLA is ...

Below is Validea's guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow, REGN rates highest using our Value Investor model based on the published ...

Vertex is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Regeneron (REGN), a stock from the same industry, has gained 7.9%. The company reported its results for ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on Regeneron (REGN – Research Report), with a price ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) shares reached a new 52-week low on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $1,100.00 to ...